{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T21:45:44Z","timestamp":1794865544444,"version":"4.9.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,3]],"date-time":"2019-01-03T00:00:00Z","timestamp":1546473600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12885-018-5235-3","type":"journal-article","created":{"date-parts":[[2019,1,3]],"date-time":"2019-01-03T07:55:37Z","timestamp":1546502137000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Prevalence of BRCA1 and BRCA2 pathogenic and likely pathogenic variants in non-selected ovarian carcinoma patients in Brazil"],"prefix":"10.1186","volume":"19","author":[{"given":"Deborah Porto","family":"Cotrim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana Regina Gon\u00e7alves","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Paix\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diogo Cordeiro","family":"de Queiroz Soares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rima","family":"Jbili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha Carvalho","family":"Pandolfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila","family":"Cezana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carine","family":"de C\u00e1ssia Mauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrique","family":"Mantoan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graziele","family":"Bovolim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"de Brot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovana Tardin","family":"Torrezan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirce Maria","family":"Carraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glauco","family":"Baiocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Nirvana","family":"da Cruz Formiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1631-0105","authenticated-orcid":false,"given":"Alexandre A. B. A.","family":"da Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,3]]},"reference":[{"key":"5235_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7\u201330.","journal-title":"CA Cancer J Clin"},{"key":"5235_CR2","volume-title":"Estimativa 2018. Incid\u00eancia do C\u00e2ncer no Brasil","author":"Instituto Nacional De C\u00e2ncer (Brasil)","year":"2018","unstructured":"Instituto Nacional De C\u00e2ncer (Brasil). Estimativa 2018. Incid\u00eancia do C\u00e2ncer no Brasil. Rio de Janeiro: INCA; 2018. [INCA Web site] Available at: \n                    http:\/\/www1.inca.gov.br\/estimativa\/2018\/\n                    \n                  . Accessed 13 Sept 2018."},{"key":"5235_CR3","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/S0140-6736(15)01224-6","volume":"387","author":"IJ Jacobs","year":"2016","unstructured":"Jacobs IJ, Menon U, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi K, et al. Ovarian cancer screening and mortality in the UK collaborative trial of ovarian Cancer screening (UKCTOCS): a randomised controlled trial. Lancet. 2016;387:945\u201356.","journal-title":"Lancet"},{"key":"5235_CR4","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1200\/JCO.2016.69.9330","volume":"35","author":"AN Rosenthal","year":"2017","unstructured":"Rosenthal AN, Fraser LSM, Philpott S, Manchanda R, Burnell M, Badman P, et al. Evidence of stage shift in women diagnosed with ovarian Cancer during phase II of the United Kingdom familial ovarian Cancer screening study. J Clin Oncol. 2017;35:1411\u201320.","journal-title":"J Clin Oncol"},{"key":"5235_CR5","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips K-A, Mooij TM, Roos-Blom M-J, et al. Risks of breast, ovarian, and contralateral breast Cancer for BRCA1and BRCA2Mutation carriers. JAMA. 2017;317:2402\u201315.","journal-title":"JAMA"},{"key":"5235_CR6","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12905-014-0150-5","volume":"14","author":"C Marchetti","year":"2014","unstructured":"Marchetti C, De Felice F, Palaia I, Perniola G, Musella A, Musio D, et al. Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers. BMC Womens Health. 2014;14:150\u20136.","journal-title":"BMC Womens Health"},{"key":"5235_CR7","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","volume":"18","author":"E Pujade-Lauraine","year":"2017","unstructured":"Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18:1274\u201384.","journal-title":"Lancet Oncol"},{"key":"5235_CR8","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","volume":"390","author":"RL Coleman","year":"2017","unstructured":"Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:1949\u201361.","journal-title":"Lancet"},{"key":"5235_CR9","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","volume":"375","author":"MR Mirza","year":"2016","unstructured":"Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375:2154\u201364.","journal-title":"N Engl J Med"},{"key":"5235_CR10","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1086\/318787","volume":"68","author":"HA Risch","year":"2001","unstructured":"Risch HA, McLaughlin JR, Cole DEC, Rosen B, Bradley L, Kwan E, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian Cancer. Am J Hum Genet. 2001;68:700\u201310.","journal-title":"Am J Hum Genet"},{"key":"5235_CR11","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1002\/cncr.21536","volume":"104","author":"T Pal","year":"2005","unstructured":"Pal T, Permuth-Wey J, Betts JA, Krischer JP, Fiorica J, Arango H, et al. BRCA1and BRCA2mutations account for a large proportion of ovarian carcinoma cases. Cancer. 2005;104:2807\u201316.","journal-title":"Cancer"},{"key":"5235_CR12","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1093\/jnci\/djj465","volume":"98","author":"HA Risch","year":"2006","unstructured":"Risch HA, McLaughlin JR, Cole DEC, Rosen B, Bradley L, Fan I, et al. Population BRCA1 and BRCA2 mutation frequencies and Cancer Penetrances: a kin\u2013cohort study in Ontario, Canada. J Natl Cancer Inst. 2006;98:1694\u2013706.","journal-title":"J Natl Cancer Inst"},{"key":"5235_CR13","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.ygyno.2011.01.020","volume":"121","author":"S Zhang","year":"2011","unstructured":"Zhang S, Royer R, Li S, McLaughlin JR, Rosen B, Risch HA, et al. Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecol Oncol. 2011;121:353\u20137.","journal-title":"Gynecol Oncol"},{"key":"5235_CR14","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.ygyno.2011.10.027","volume":"124","author":"AO Rodr\u00edguez","year":"2012","unstructured":"Rodr\u00edguez AO, Llacuachaqui M, Pardo GG, Royer R, Larson G, Weitzel JN, et al. BRCA1 and BRCA2 mutations among ovarian cancer patients from Colombia. Gynecol Oncol. 2012;124:236\u201343.","journal-title":"Gynecol Oncol"},{"key":"5235_CR15","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","volume":"30","author":"K Alsop","year":"2012","unstructured":"Alsop K, Fereday S, Meldrum C, deFazio A, Emmanuel C, George J, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation\u2013positive women with ovarian Cancer: a report from the Australian ovarian Cancer study group. J Clin Oncol. 2012;30:2654\u201363.","journal-title":"J Clin Oncol"},{"key":"5235_CR16","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"TCGA","year":"2011","unstructured":"TCGA. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609\u201315.","journal-title":"Nature"},{"key":"5235_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13053-015-0044-z","volume":"14","author":"A Synowiec","year":"2016","unstructured":"Synowiec A, Wcis\u0142o G, Bodnar L, G\u00f3rski B, Szenajch J, Szarlej-Wcis\u0142o K, et al. Clinical features and outcomes of germline mutation BRCA1-linked versus sporadic ovarian cancer patients. Hered Cancer Clin Pract. 2016;14:1\u20138.","journal-title":"Hered Cancer Clin Pract"},{"key":"5235_CR18","doi-asserted-by":"publisher","first-page":"e0186043","DOI":"10.1371\/journal.pone.0186043","volume":"12","author":"P Harter","year":"2017","unstructured":"Harter P, Hauke J, Heitz F, Reuss A, Kommoss S, Marm\u00e9 F, et al. Prevalence of deleterious germline variants in risk genes including BRCA1\/2 in consecutive ovarian cancer patients (AGO-TR-1). PLoS One. 2017;12:e0186043\u201312.","journal-title":"PLoS One"},{"key":"5235_CR19","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1097\/IGC.0000000000001065","volume":"27","author":"X Wu","year":"2017","unstructured":"Wu X, Wu L, Kong B, Liu J, Yin R, Wen H, et al. The first Nationwide multicenter prevalence study of germline BRCA1 and BRCA2 mutations in Chinese ovarian Cancer patients. Int J Gynecol Cancer. 2017;27:1650\u20137.","journal-title":"Int J Gynecol Cancer"},{"key":"5235_CR20","doi-asserted-by":"crossref","unstructured":"Li A, Xie R, Zhi Q, Deng Y, Wu Y, Li W, et al. BRCA germline mutations in an unselected nationwide cohort of Chinese patients with ovarian cancer and healthy controls. Gynecol Oncol. 2018;151:145\u201352.","DOI":"10.1016\/j.ygyno.2018.07.024"},{"key":"5235_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3802\/jgo.2018.29.e1","volume":"29","author":"MC Choi","year":"2018","unstructured":"Choi MC, Bae J-S, Jung SG, Park H, Joo WD, Song SH, et al. Prevalence of germline BRCAmutations among women with carcinoma of the peritoneum or fallopian tube. J Gynecol Oncol. 2018;29:1\u20139.","journal-title":"J Gynecol Oncol"},{"key":"5235_CR22","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s10549-017-4635-4","volume":"168","author":"A-J Alhuqail","year":"2018","unstructured":"Alhuqail A-J, Alzahrani A, Almubarak H, Al-Qadheeb S, Alghofaili L, Almoghrabi N, et al. High prevalence of deleterious BRCA1 and BRCA2 germline mutations in Arab breast and ovarian cancer patients. Breast Cancer Res Treat. 2018;168:695\u2013702.","journal-title":"Breast Cancer Res Treat"},{"key":"5235_CR23","first-page":"1374","volume":"49","author":"K Rust","year":"2018","unstructured":"Rust K, Spiliopoulou P, Tang CY, Bell C, Stirling D, Phang T, et al. Routine germline BRCA1and BRCA2testing in patients with ovarian carcinoma: analysis of the Scottish real-life experience. BJOG. 2018;49:1374\u20138.","journal-title":"BJOG"},{"key":"5235_CR24","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1001\/jamaoncol.2015.5495","volume":"2","author":"BM Norquist","year":"2016","unstructured":"Norquist BM, Harrell MI, Brady MF, Walsh T, Lee MK, Gulsuner S, et al. Inherited mutations in women with ovarian carcinoma. JAMA Oncol. 2016;2:482\u20139.","journal-title":"JAMA Oncol"},{"key":"5235_CR25","doi-asserted-by":"crossref","unstructured":"Maistro S, Teixeira N, Encinas G, Katayama MLH, Niewiadonski VDT, Cabral LG, et al. Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil. BMC Cancer. 2016;16:934.","DOI":"10.1186\/s12885-016-2966-x"},{"key":"5235_CR26","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.cancergen.2015.11.003","volume":"209","author":"H Schayek","year":"2016","unstructured":"Schayek H, De Marco L, Starinsky-Elbaz S, Rossette M, Laitman Y, Bastos-Rodrigues L, et al. The rate of recurrent BRCA1, BRCA2, and TP53 mutations in the general population, and unselected ovarian cancer cases, in Belo Horizonte, Brazil. Cancer Genet. 2016;209:50\u20132.","journal-title":"Cancer Genet"},{"key":"5235_CR27","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"on behalf of the ACMG Laboratory Quality Assurance Committee, Richards S, Aziz N, Bale S, Bick D, Das S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the association for molecular pathology. Genet Med. 2015;17:405\u201323.","journal-title":"Genet Med"},{"key":"5235_CR28","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1093\/jnci\/92.18.1534","volume":"92","author":"I Vergote","year":"2000","unstructured":"Vergote I, Rustin GJS, Eisenhauer EA, Kristensen GB, Pujade-Lauraine E, Parmar MKB, et al. Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian Cancer]. J Natl Cancer Inst. 2000;92:1534\u20135.","journal-title":"J Natl Cancer Inst"},{"key":"5235_CR29","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1093\/jnci\/djh081","volume":"96","author":"GJS Rustin","year":"2004","unstructured":"Rustin GJS, Quinn M, Thigpen T, Bois d A, Pujade-Lauraine E, Jakobsen A, et al. Re: new guidelines to evaluate the response to treatment in solid tumors (ovarian Cancer). J Natl Cancer Inst. 2004;96:487\u20138.","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"5235_CR30","doi-asserted-by":"publisher","first-page":"e0186043","DOI":"10.1371\/journal.pone.0186043","volume":"12","author":"P Harter","year":"2017","unstructured":"Harter P, Hauke J, Heitz F, Reuss A, Kommoss S, Marm\u00e9 F, et al. Prevalence of deleterious germline variants in risk genes including BRCA1\/2 in consecutive ovarian cancer patients (AGO-TR-1). PLoS One. 2017;12(10):e0186043.","journal-title":"PLoS One"},{"key":"5235_CR31","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1007\/s00432-009-0607-3","volume":"135","author":"MC Lim","year":"2009","unstructured":"Lim MC, Kang S, Seo S-S, Kong S-Y, Lee B-Y, Lee S-K, et al. BRCA1 and BRCA2 germline mutations in Korean ovarian cancer patients. J Cancer Res Clin Oncol. 2009;135:1593\u20139.","journal-title":"J Cancer Res Clin Oncol"},{"key":"5235_CR32","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1897-4287-9-12","volume":"9","author":"IP Ewald","year":"2011","unstructured":"Ewald IP, Izetti P, Vargas FR, Moreira MA, Moreira AS, Moreira-Filho CA, et al. Prevalence of the BRCA1 founder mutation c.5266dupin Brazilian individuals at-risk for the hereditary breast and ovarian cancer syndrome. Hered Cancer Clin Pract. 2011;9:12.","journal-title":"Hered Cancer Clin Pract"},{"issue":"6","key":"5235_CR33","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1002\/humu.1136","volume":"17","author":"A Vega","year":"2018","unstructured":"Vega A, Campos B, Bressac-de-Paillerets B, Bond PM, Janin N, Douglas FS, et al. The R71G BRCA is a founder Spanish mutation and leads to aberrant splicing of the transcript. Hum Mutat. 2018;17(6):520\u20131.","journal-title":"Hum Mutat"},{"key":"5235_CR34","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1634\/theoncologist.2015-0416","volume":"21","author":"CA Ossa","year":"2016","unstructured":"Ossa CA, Torres D. Founder and recurrent mutations in BRCA1 and BRCA2 genes in Latin American countries: state of the art and literature review. Oncologist. 2016;21:832\u20139.","journal-title":"Oncologist"},{"key":"5235_CR35","doi-asserted-by":"publisher","first-page":"4071","DOI":"10.1200\/JCO.2016.68.4316","volume":"34","author":"J Balma\u00f1a","year":"2016","unstructured":"Balma\u00f1a J, Digiovanni L, Gaddam P, Walsh MF, Joseph V, Stadler ZK, et al. Conflicting interpretation of genetic variants and Cancer risk by commercial laboratories as assessed by the prospective registry of multiplex testing. J Clin Oncol. 2016;34:4071\u20138.","journal-title":"J Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-5235-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-018-5235-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-5235-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,2]],"date-time":"2020-01-02T19:13:10Z","timestamp":1577992390000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-018-5235-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,3]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["5235"],"URL":"https:\/\/doi.org\/10.1186\/s12885-018-5235-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,3]]},"assertion":[{"value":"18 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The A.C. Camargo Cancer Center Ethics Committee approved the study (CEP# 2450\/17). The need for informed consent has been waived by the A.C. Camargo Cancer Center Ethics Committee.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"4"}}